Back to top
more

Embecta Corp. (EMBC)

(Delayed Data from NSDQ)

$14.34 USD

14.34
1,221,964

-0.83 (-5.47%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $14.34 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 245)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ascend Wellness Holdings, Inc. (AAWH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ascend Wellness Holdings, Inc. (AAWH) delivered earnings and revenue surprises of -30% and 1.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DocGo Inc. (DCGO) Tops Q3 Earnings Estimates

by Zacks Equity Research

Motion Acquisition (DCGO) delivered earnings and revenue surprises of 25% and 0.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cencora (COR) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Cencora (COR) delivered earnings and revenue surprises of 4.05% and 1.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Premier, Inc. (PINC) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Premier (PINC) delivered earnings and revenue surprises of 30.77% and 7.79%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bausch + Lomb (BLCO) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Bausch + Lomb (BLCO) delivered earnings and revenue surprises of 6.25% and 2.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump

by Zacks Equity Research

EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes.

Zacks Equity Research

Embecta Corp. (EMBC) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Zacks Equity Research

Embecta Corp. (EMBC) Just Overtook the 200-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

Zacks Equity Research

Embecta Corp. (EMBC) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Embecta Corp. (EMBC) delivered earnings and revenue surprises of 54.17% and 0.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Viatris (VTRS) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of 1.47% and 0.49%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Embecta Corp. (EMBC) Q3 Earnings Expected to Decline

by Zacks Equity Research

Embecta Corp. (EMBC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is the Options Market Predicting a Spike in Embecta Corp. (EMBC) Stock?

by Zacks Equity Research

Investors need to pay close attention to Embecta Corp. (EMBC) stock based on the movements in the options market lately.

Zacks Equity Research

Strength Seen in Embecta Corp. (EMBC): Can Its 6.9% Jump Turn into More Strength?

by Zacks Equity Research

Embecta Corp. (EMBC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Best Value Stocks to Buy for May 15th

by Zacks Equity Research

CIXXF, JXN and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 15, 2024.

Zacks Equity Research

Cencora (COR) Q2 Earnings Top Estimates

by Zacks Equity Research

Cencora (COR) delivered earnings and revenue surprises of 4.11% and 2.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Best Value Stocks to Buy for February 12th

by Zacks Equity Research

XRX, EMBC and HMN made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 12, 2023.

Zacks Equity Research

Embecta Corp. (EMBC) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Embecta Corp. (EMBC) delivered earnings and revenue surprises of 35.56% and 4.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Premier, Inc. (PINC) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 11.11% and 1.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alignment Healthcare (ALHC) Moves 13.2% Higher: Will This Strength Last?

by Zacks Equity Research

Alignment Healthcare (ALHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Beacon Roofing Supply, Embecta and Western Midstream Partners

by Zacks Equity Research

Beacon Roofing Supply, Embecta and Western Midstream Partners have been highlighted in this Investment Ideas article.

Shaun Pruitt headshot

Time to Buy These Intriguing Additions to Zacks Rank #1 (Strong Buy) List

by Shaun Pruitt

Several intriguing stocks were recently added to the Zacks Rank #1 (Strong Buy) list this week and shouldn't be overlooked as we round out what has been an exciting year for the stock market.

Zacks Equity Research

Embecta Corp. (EMBC) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Embecta Corp. (EMBC) delivered earnings and revenue surprises of 40.48% and 1.75%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

IceCure Medical Ltd. (ICCM) delivered earnings and revenue surprises of 0% and 65.58%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Embecta Corp. (EMBC) Q4 Earnings Expected to Decline

by Zacks Equity Research

Embecta Corp. (EMBC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.